Noom's Two-Lane GLP-1 Strategy

Noom is turning GLP-1 access into a two lane funnel, one lane for price sensitive users, one lane for users who want branded supply with less friction. That matters because obesity telehealth is no longer won just by writing a prescription. It is won by matching each patient to a workable path, then keeping them inside one app for intake, coaching, refill tracking, side effect management, and upsells into broader weight care.

• The microdose offer is a customer acquisition wedge. At $99 to start, then $199 per month, it sits well below branded cash pay vial pricing and gives Noom a way to convert people who are curious about GLP-1s but scared off by cost or side effects. That is especially valuable in a category where long treatment duration drives lifetime value.
  1 sacra 2 sacra 3 noom
• The LillyDirect and Gifthealth integration shows the other half of the play. Instead of only monetizing compounded supply, Noom also keeps a role when a patient qualifies for branded Zepbound, with fill status and shipping updates inside the Noom interface. Ro moved in a similar direction as branded access became more important after compounding tightened.
  1 sacra 3 noom 4 sacra 5 lilly
• This is more defensible than a drugs only model because Noom already has a large weight loss app, coaching layer, and behavior change workflow. The same app that logs meals and habits can also support dose titration, side effect education, and adherence, which makes medication access feel like an extension of the core product rather than a separate checkout flow.
  1 sacra 2 sacra 3 noom

The next phase is for GLP-1 access to become cheaper and more standardized, while the winning platforms capture value from guidance and retention around the drug. Noom is positioning for that shift now. As compounded supply narrows and branded distribution expands, the company can keep routing members into whichever option is available, legal, and affordable, while using the app to hold onto the customer relationship.